Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reissue Patent
2000-02-15
2002-09-10
Spivack, Phyllis G. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
Reissue Patent
active
RE037838
ABSTRACT:
DESCRIPTION
This invention relates to the common use of estrogens and gestagens for the production of a combination preparation for oral contraception and a corresponding pack containing this combination preparation.
Combination preparations for oral contraception are already known, for example, Femovan® [DE-PS 2 546 062] or Marvelon® [DE-OS 2 361 120]. These preparations consist of 21 active ingredient-containing (estrogen/gestagen) dosage units and 7 active ingredient-free coated tablets (sugar pills; placebos). The dose to be administered daily is uniformly high in each case (so-called single-phase preparations) and produces the desired contraceptive effect in the entire intake period and in the intake pause or during the intake of the placebos. In most preparations, a 7-day interruption of the intake of active ingredient-containing dosage units was considered necessary until quite recently to trigger a reliable withdrawal bleeding and thus to achieve a satisfactory cycle control.
Other preparations, which exhibit more than 21 dosage units containing an estrogenic and progestational active ingredient, and in which the intake pause is partially (Ijzerman, Pasquale) or completely (Kuhl) bridged over by estrogen-containing dosage units. In this case, it is possible that the synthetic estrogen ethinylestradiol otherwise contained in oral contraceptives is replaced partially or completely by a conjugated estrogen, preferably estradiol.
A combination preparation for substitution therapy and contraception for females before menopause (approximately starting from the 40th year of life) is known from EP-A-0 253 607. This combination preparation contains an estrogen from the group
17&bgr;-Estradiol,
ethinylestradiol and
mestranol
as well as a gestagen from the group
levonorgestrel,
gestodene,
desogestrel,
3-ketodesogestrel and
norethindrone.
A thus selected composition is to offset hormonal irregularities in the transition phase of premenopause and to help alleviate the symptoms caused by the hormonal changeover of the female organism in this phase. Such a composition simultaneously assures a premenopausal female the contraceptive protection still necessary at this age.
The development of new oral contraceptives for females of reproductive age before premenopause was characterized during the last twenty years above all by the reduction of the estrogen and gestagen dosages.
REFERENCES:
patent: 4129564 (1978-12-01), Wiechert et al.
patent: 5569652 (1996-10-01), Beier et al.
patent: 5756490 (1998-05-01), Lachnit et al.
patent: 30 232337 (1982-01-01), None
patent: 44 11 585 (1995-10-01), None
patent: 0 253 607 (1988-01-01), None
patent: 0 398 460 (1990-11-01), None
patent: 0 491 415 (1992-06-01), None
patent: 0 491 438 (1992-06-01), None
patent: 640 343 (1995-03-01), None
patent: WO 95/26730 (1995-10-01), None
patent: WO 98/04246 (1998-02-01), None
patent: WO 98/04265 (1998-02-01), None
patent: WO 98/04267 (1998-02-01), None
patent: WO 98/04268 (1998-02-01), None
PCT Search Report dated May 12, 1995.*
G.B. Melis, et al., Contraception, “A Comparative Study on the Effects of a Monophasic Pill Containing Desogestrel Plus 20 &mgr;g Ethinylestradiol, a Triphasic Combination Levonorgestrel and a Monophasic Combination Containing gestrodene on Coagulatory Factors”, vol. 43, No. 1, pp. 23-30 (Jan. 1991), [including abstract].
A.R. Genazzani, et al. (Ed), Progress in Gynecology and Obstetrics, “Multicenter Clinical Trial on the new Oral Contraceptive Containing 20 &mgr;g Ethinylestradiol”, Chapter 1, pp. 747-756, (1990).
Parke Davis package insert for Loestrin, Jun., 1993.
W. Oelkers et al., “Journal of Clinical Endocrinology and Metabolism”, p. 73, pp. 837-842, (1991).
W. Oelkers et al., “Acta Endocrinologica”, Suppl. 4, p. 71, #97, (1992) (Abstract Only).
W. Oelkers et al., “Journal of Clinical Endocrinology and Metabolism”, 80, pp. 1816-1821.
Elstein et al., Zentralblatt fur Gynäkologie, 117, pp. 559-565, (1995).
Schillinger et al., “Arzneim.-Forsch.”, 26, pp. 2242-2245, (Abstract only), (1976).
Huernpel et al., Contraception, 16, pp. 199-216 (Abstract only), (1977).
Düsterberg et al., “Acta Obstet Gynecol Scand. Suppl.”, 88, pp. 27-31, (1979).
Leis et al., “Geburtshilfe Frauenheilkd”, 39, pp. 54-57 (Abstract only), (1979).
Klebe et al. “Arch Gynecol”, 234, pp. 113-120, (Abstract only) (1985).
Holdaway et al., “Acta Endocrinol”, 109, 522-529, (Abstract only) (1985).
Kuhl et al., “Contraception”, pp. 467-482, (1985).
Larsson-Cohn et al., “Acta Obstet Gynecol Scand”, 65, pp. 125-128, (Abstract only) (1986).
Calaf-Alsina et al., “Obstet Gynecol”, 69, pp. 255-258, (Abstract only) (1987).
Spona et al., “Gynecol Obstet Invest”, 23, pp. 184-193, (1987).
Jandrain et al., “Am J. Obstet Gynecol”, 163, pp. 378-381, (1990).
Porcile et al., “Fertiliry and Sterility”, 55, pp. 877-881, (Abstract only) (1991).
Scheen et al., “Fertility and Sterility”, 59, pp. 797-802, (Abstract only) (1993).
Kuhnz et al., “Contraception”, 48, pp. 557-575, (1993).
M. Elstein, “Advaces in Contraception”, 12, pp. 155-156, (1996).
Foidart et al., “Int'l J. Gynecol & Obstet”, 46, Suppl. 3, p. 11, (1994).
Oelkers et al., “Advances in Constraception”, 7, Suppl. 3, pp. 195-206 (1991).
Filshie and Guillebaud, eds., “Contraception: Science and Practice”, 69-93 (1989).
J. Guillebaud,Br. J Family Planning,12 (Suppl.), 35-43 (1987).
Van Keep et al., eds. “The Controvresial Climactoric”, MTP Press Limited, 9-18 (1981).
German Pharmacopeia, 9th Edition, 1986—English Translation.
Düsterberg Bernd
Lüdicke Frank
Spona Jürgen
Schering Aktiengesellschaft
Spivack Phyllis G.
LandOfFree
Composition for contraception does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Composition for contraception, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Composition for contraception will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2831427